Related Experiment Video

Updated: Dec 9, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Michela Piezzo1, Stefania Cocco1, Roberta Caputo1

  • 1Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Naples, Italy.

International Journal of Molecular Sciences
|September 9, 2020
PubMed

Insights

CDK4/6 inhibitors improve outcomes in metastatic breast cancer but resistance is a challenge. Research focuses on understanding resistance mechanisms and developing new combination therapies for better patient results.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle deregulation via the cyclin D/CDK/pRb pathway is common in breast cancer.
  • Cyclin-dependent kinase (CDK) 4 and 6 inhibitors target this pathway.
  • Three CDK4/6 inhibitors are FDA-approved for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer.

Purpose of the Study:

  • To review current knowledge on CDK4/6 inhibitors in breast cancer.
  • To discuss biomarkers for predicting response to CDK4/6 inhibitors.
  • To explore novel combination treatment strategies.

Main Methods:

  • Literature review of clinical and translational research.
  • Analysis of mechanisms of sensitivity and resistance to CDK4/6 inhibition.
  • Synthesis of data on biomarker discovery and combination therapies.

Main Results:

  • CDK4/6 inhibitors have improved clinical outcomes in HR+, HER2- metastatic breast cancer.
  • Intrinsic and acquired resistance limit treatment efficacy.
  • Ongoing research aims to identify new biomarkers and effective combination strategies.

Conclusions:

  • Understanding CDK4/6 inhibitor resistance is crucial for improving breast cancer treatment.
  • Biomarker discovery and novel combination therapies hold promise for overcoming resistance.
  • Further research is needed to optimize therapeutic strategies and patient outcomes.
Keywords:
CDK4/6 inhibitorscancercell cyclecyclin-dependent kinasehormone receptorshormone therapymetastatic breast cancertherapies

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.3K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
127.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K